# Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers

> **NCT05621655** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MAXVAX Biotechnology Limited Liability Company** · enrollment: 1512 (actual)

## Conditions studied

- Rotavirus Infections
- Rotavirus Gastroenteritis

## Interventions

- **BIOLOGICAL:** Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine
- **BIOLOGICAL:** High dose Recombinant Trivalent Subunit Rotavirus Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05621655
- **Lead sponsor:** MAXVAX Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-08
- **Primary completion:** 2023-04-29
- **Final completion:** 2024-12
- **Target enrollment:** 1512 (ACTUAL)
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621655, "Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05621655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*